Novavax, Inc. (NASDAQ:NVAX)‘s stock had its “neutral” rating reaffirmed by stock analysts at Cantor Fitzgerald in a research report issued to clients and investors on Thursday. They currently have a $2.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price would suggest a potential upside of 39.86% from the company’s previous close.

The analysts wrote, “RSV maternal vaccination likely primary value driver in 2017. We believe investors will be keenly focused on the RSV vaccine when used in the context of maternal vaccination, particularly given the failure of the elderly subject RSV pivotal trial late last year. Clinical data suggest that the vaccine is immunogenic in pregnant women and that anti-RS F protein antibodies are efficiently transferred across the placenta to the fetus.””

A number of other brokerages have also recently commented on NVAX. Chardan Capital reiterated a “neutral” rating and issued a $1.50 target price on shares of Novavax in a research note on Friday, November 11th. FBR & Co set a $12.00 target price on shares of Novavax and gave the stock a “buy” rating in a research note on Friday, November 11th. J P Morgan Chase & Co reiterated a “hold” rating on shares of Novavax in a research note on Thursday, November 10th. Zacks Investment Research upgraded shares of Novavax from a “hold” rating to a “buy” rating and set a $1.50 target price on the stock in a research note on Tuesday, November 15th. Finally, Wedbush reiterated a “neutral” rating and issued a $1.50 target price (down from $2.00) on shares of Novavax in a research note on Friday, November 11th. Eight investment analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company. Novavax has an average rating of “Hold” and an average target price of $6.17.

Analyst Recommendations for Novavax (NASDAQ:NVAX)

Shares of Novavax (NASDAQ:NVAX) traded down 1.38% during trading on Thursday, hitting $1.43. 7,171,320 shares of the stock were exchanged. Novavax has a 52 week low of $1.16 and a 52 week high of $8.49. The firm’s market capitalization is $387.81 million. The stock’s 50 day moving average price is $1.33 and its 200 day moving average price is $4.06.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings results on Wednesday, November 9th. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.26) by $0.02. The company had revenue of $3.20 million for the quarter, compared to analysts’ expectations of $4.02 million. Novavax had a negative net margin of 1,908.41% and a negative return on equity of 189.14%. Novavax’s revenue was down 50.8% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.12) EPS. On average, equities analysts predict that Novavax will post ($1.05) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Novavax, Inc. (NVAX) Stock Rating Reaffirmed by Cantor Fitzgerald” was originally posted by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this article can be accessed at http://www.watchlistnews.com/novavax-inc-nvax-receives-hold-rating-from-cantor-fitzgerald/1060527.html.

Institutional investors have recently added to or reduced their stakes in the stock. Principal Financial Group Inc. raised its position in Novavax by 1.1% in the third quarter. Principal Financial Group Inc. now owns 48,096 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 536 shares in the last quarter. Compagnie Lombard Odier SCmA acquired a new position in Novavax during the second quarter valued at approximately $102,000. Veritable L.P. acquired a new position in Novavax during the second quarter valued at approximately $102,000. Geduld E E acquired a new position in Novavax during the third quarter valued at approximately $104,000. Finally, Wedbush Securities Inc. raised its position in Novavax by 3.1% in the third quarter. Wedbush Securities Inc. now owns 50,344 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 1,534 shares in the last quarter. 61.50% of the stock is currently owned by institutional investors.

Novavax Company Profile

Novavax, Inc (Novavax) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases.

5 Day Chart for NASDAQ:NVAX

Receive News & Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.